press-release
Summary
ANTWERP, Belgium - 18 January, 2023: Koios Care, a HealthTech company that develops digital, daily activity biomarkers towards the progression of neurodegenerative diseases, and specifically Parkinsons Disease, has secured funding from Lumiares.The funding will be used to support the continued development and refinement of Koios Cares innovative technology, which uses advanced AI algorithms to unobtrusively detect clinically meaningful signs of Quality of Life deterioration. This funding will allow us to deliver clinically meaningful products towards improving patient outcomes and Quality of Life, said Dimitris Iakovakis, cofounder and CTO of the company.The two main founders have been collaborating in digital health for Parkinsons research the last 6 years. During this time, they developed digital biomarkers from passively collected data that aim to assist early detection of Parkinsons and assessment of Quality of Life.Koios Care builds digital biomarkers and products that interface between providers and patients, tackling the needs for early detection, disease progression monitoring towards better care of neurodegenerative diseases. "We believe in the potential of their technology to make a real impact in the field of healthcare, and we are confident in their ability to continue to develop and bring their solutions to market. Koios Care is dedicated to improving the lives of individuals affected by neurodegenerative diseases through the development of innovative technology and digital solutions.More information is available at www.koios.care or via info@koios.care